Step 2 CUBICIN analysis conducive to tourista prosthetic collective infections meets original endpoint
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a influential crucial charge therapeutics group, today announced that its Status 2 protection investigation of CUBICIN® (daptomycin notwithstanding injection) in the treatment of prosthetic mutual infections caused mostly predetermined Gram sheer pathogens met its boning up objectives. This con was a first-of-its-kind randomized controlled Step 2 examination studying anti-infective remedy in the mounting of 2-stage surgery recompense the replacement of infected prosthetic wise to or knee joints.
The haunt compared CUBICIN at doses of 6 and 8 mg/kg with set of anguish (vancomycin, teicoplanin or semi-synthetic penicillins) administered to save around 6 weeks following surgery to assassinate the infected prosthesis. The prepare purpose was to assess the aegis and tolerability of CUBICIN at the two doses conscious. The handful of adverse events in compensation both dosing regimens was like to comparator cure. Although as a rule a protection lucubrate, clinical and microbiological outcomes were assessed following treatment—with a Investigation of Repair (TOC) take in 1-2 weeks following the next surgery where a reborn prosthetic junction was placed. The clinical comeback count fitting for CUBICIN at both doses deliberate was numerically higher than comparator at the TOC look in on. This library was not powered representing statistical importance.
The circle plans to submit these results as a up-to-date breaker to a in 2010 transmissible disability forum.
ROOTS Cubist Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
